Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.
Adrenergic beta-Antagonists
/ therapeutic use
Aged
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Cardiovascular Agents
/ therapeutic use
Cohort Studies
Coronary Artery Bypass
Coronary Artery Disease
/ drug therapy
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Male
Middle Aged
Platelet Aggregation Inhibitors
/ therapeutic use
Practice Patterns, Physicians'
Secondary Prevention
Socioeconomic Factors
Survival Rate
Sweden
coronary artery bypass grafting
medication
mortality
secondary prevention
socioeconomic status
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
03 03 2020
03 03 2020
Historique:
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
18
3
2021
Statut:
ppublish
Résumé
Background Low income and short education have been found to be independently associated with inferior survival after coronary artery bypass grafting (CABG), whereas the use of secondary prevention medications is associated with improved survival. We investigated whether underusage of secondary prevention medications contributes to the inferior long-term survival in CABG patients with a low income and short education. Methods and Results Patients who underwent CABG in Sweden between 2006 to 2015 and survived at least 6 months after discharge (n=28 448) were included in a population-based cohort study. Individual patient data from 5 national registries, including the SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) registry, covering dispensing of secondary prevention medications (statins, platelet inhibitors, β-blockers, and RAAS inhibitors), socioeconomic factors, patient characteristics, comorbidity, and long-term mortaity were merged. All-cause mortality risk was estimated using multivariable Cox regression models adjusted for patient characteristics, baseline comorbidities, time-updated secondary prevention medications, and socioeconomic status. Long-term mortality was higher in patients with a low income and short education. Statins and platelet inhibitors were dispensed less often to patients with a low income, both at baseline and after 8 years. The decline in dispensing over time was steeper for low-income patients. Short education was not associated with reduced dispensing of any secondary prevention medication. Use of statins (adjusted hazard ratio=0.57 [95% CI, 0.53-0.61]), RAAS inhibitors (adjusted hazard ratio=0.78 [0.73-0.84]), and platelet inhibitors (adjusted hazard ratio=0.74 [0.68-0.80]) were associated with reduced long-term mortality irrespective of socioeconomic status. Conclusions Secondary prevention medications are dispensed less often after CABG to patients with low income. Underusage of secondary prevention medications after CABG is associated with increased mortality risk independently of income and extent of education.
Identifiants
pubmed: 32114890
doi: 10.1161/JAHA.119.015491
pmc: PMC7335537
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Cardiovascular Agents
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e015491Références
Interact Cardiovasc Thorac Surg. 2018 Jul 1;27(1):67-74
pubmed: 29452368
J Am Heart Assoc. 2012 Aug 29;1(5):e002733
pubmed: 26600570
J Am Coll Cardiol. 2013 Jan 22;61(3):295-301
pubmed: 23246391
Lancet. 2017 Mar 11;389(10073):1055-1065
pubmed: 28290995
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Am J Manag Care. 2005 Jul;11(7):449-57
pubmed: 16044982
Circulation. 2015 Mar 10;131(10):927-64
pubmed: 25679302
Am Heart J. 2004 Jun;147(6):1047-53
pubmed: 15199354
Int J Cardiol. 2015 Mar 1;182:141-7
pubmed: 25577750
BMJ Open. 2015 Jun 29;5(6):e008287
pubmed: 26124512
J Am Coll Cardiol. 2018 Feb 13;71(6):591-602
pubmed: 29420954
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
Circ Cardiovasc Qual Outcomes. 2016 Nov;9(6):704-713
pubmed: 27756795
Circulation. 2013 Sep 10;128(11 Suppl 1):S219-25
pubmed: 24030410
J Am Heart Assoc. 2019 Mar 19;8(6):e011490
pubmed: 30852925
Heart. 2010 Oct;96(20):1617-21
pubmed: 20801780
Eur Heart J. 2020 May 1;41(17):1653-1661
pubmed: 31638654
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
J Thorac Cardiovasc Surg. 2007 Oct;134(4):932-8
pubmed: 17903510
Circulation. 2007 Sep 11;116(11 Suppl):I207-12
pubmed: 17846305
Circulation. 2008 Oct 28;118(18):1785-92
pubmed: 18852363
J Am Coll Cardiol. 2015 Oct 27;66(17):1888-97
pubmed: 26493661
Eur Stroke J. 2016 Jun;1(2):101-107
pubmed: 31008271
Ann Thorac Surg. 2009 Sep;88(3):789-95; discussion 795
pubmed: 19699899
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Ann Transl Med. 2017 Mar;5(6):140
pubmed: 28462220
Eur J Cardiothorac Surg. 2018 Jan 1;53(1):5-33
pubmed: 29029110
J Epidemiol Community Health. 1998 Jun;52(6):399-405
pubmed: 9764262
Circulation. 2015 Apr 7;131(14):1269-77
pubmed: 25847979
Eur J Clin Pharmacol. 2013 Aug;69(8):1553-63
pubmed: 23588558
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Circulation. 2016 Oct 25;134(17):1238-1246
pubmed: 27777293
J Am Heart Assoc. 2020 Mar 3;9(5):e015491
pubmed: 32114890
Circulation. 2006 Jan 17;113(2):203-12
pubmed: 16401776